Israel Englander’s Regenxbio RGNX Stock Holding History

Israel Englander’s Portfolio RGNX Stock Details RGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-21,300	Closed	-$206K	–	6379
2025 Q3	$206K	Buy	+21,300	New	+$188K	﹤0.01%	5535
2019 Q3	–	Sell	-35,000	Closed	-$1.8M	–	4490
2019 Q2	$1.8M	Sell	35,000 -15,000	-30%	-$749K	﹤0.01%	2466
2019 Q1	$2.87M	Buy	+50,000	New	+$2.48M	﹤0.01%	2165
2018 Q3	–	Sell	-22,200	Closed	-$1.59M	–	4209
2018 Q2	$1.59M	Buy	+22,200	New	+$1.06M	﹤0.01%	2550
2018 Q1	–	Sell	-200,000	Closed	-$6.65M	–	4004
2017 Q4	$6.65M	Buy	200,000 +170,900	+587%	+$5.15M	0.01%	1586
2017 Q3	$959K	Buy	+29,100	New	+$655K	﹤0.01%	2540

Other funds holding RGNX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Israel Englander's RGNX Position: Q2 2026 in Review

Israel Englander increased its Regenxbio (RGNX) stake by 69% in Q2 2026, buying an estimated $1.62M and bringing the position to 480,762 shares worth $5.76M. The position accounts for ﹤0.01% of the portfolio, ranked #2852.

Israel Englander first reported a position in RGNX in Q3 2015 and has held it in 37 quarters since. The position peaked at $14.3M in Q1 2017. 164 funds tracked by Wall St. Rank hold RGNX as of Q2 2026.

Israel Englander held 480,762 shares of Regenxbio worth $5.76M as of Q2 2026.
Israel Englander bought 195,588 Regenxbio shares in Q2 2026, an estimated $1.62M.
Regenxbio made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #2852 holding.
Israel Englander first reported a position in Regenxbio in Q3 2015 and has held it in 37 quarters since.
Israel Englander's Regenxbio position peaked at $14.3M in Q1 2017.
164 funds tracked by Wall St. Rank held Regenxbio as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.